Effects of Lean Pork, High Protein Breakfast on Satiety and Metabolic Health in Pre-diabetes
Completed · Not applicable
Conditions studied: Pre-diabetes
In brief
The goal of this study is to assess the effects of consumption of a lean pork-containing, high-protein breakfast versus a refined carbohydrate-rich breakfast on satiety and cardiometabolic parameters in overweight or obese adults with pre-diabetes.
Key facts
- Study ID
- NCT02934425
- Run by
- Midwest Center for Metabolic and Cardiovascular Research
- People needed
- 22
- Starts
- 2016-08-01
- Expected to finish
- 2017-02-01
- Last updated by the study team
- 2018-05-15
Who can join
Age: 18 and older, up to 74. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Body mass index 25.0-39.9 kg/m2
- At least 1 of the following: a) capillary glycated hemoglobin 5.7-6.4%, b) fasting capillary glucose 100-125 mg/dL, or c) capillary glycated hemoglobin <5.7% and borderline fasting capillary glucose level 95-99 mg/dL and a subsequent fasting venous plasma glucose 100-125 mg/dL
- Self-identified "regular breakfast consumer" and willing to eat study foods as a breakfast meal
- Access to freezer and a food re-heating appliance
- Judged to be in good health on basis of medical history
You may not qualify if…
- Fasting laboratory test results of clinical significance (e.g., triglycerides ≥500 mg/dL, capillary glucose ≥126 mg/dL, glycated hemoglobin ≥6.5%)
- Uncontrolled hypertension
- Recent major trauma or surgical event
- Recent weight change ≥4.5 kg
- History or presence of clinically important endocrine, cardiovascular, pulmonary, biliary, or gastrointestinal disorders
- Recent history or presence of cancer (except non-melanoma skin cancer)
- History of extreme dietary habits
- Vegan or vegetarian
- History of eating disorder diagnosed by health professional
- Known intolerance or sensitivity to study products
- Unstable use of medications intended to alter lipid profile (e.g., unstable use of statins, bile acid sequestrants, cholesterol absorption inhibitor, fibrates, niacin-drug form, or omega-3-acid ethyl ester drugs)
- Recent use of foods or dietary supplements that might alter lipid metabolism (e.g., omega-3 fatty acid supplements or fortified foods, sterol/stanol products, pantethine, viscous dietary fiber supplements, red yeast supplements, garlic supplements, soy isoflavone supplements, probiotic supplements, niacin or analogues at >200 mg/d)
- Recent use of medications known to influence carbohydrate metabolism (e.g., adrenergic blockers, diuretics, hypoglycemic medications, systemic corticosteroids)
- Recent use of weight-loss drugs (including over-the-counter) or programs
- Recent history or current use of supplements and/or medications known to influence, satiety, appetite, taste, sense of smell, or weight (e.g., hypoglycemic medications and systemic corticosteroids)
- Recent use of antibiotics
- Signs or symptoms of active infection of clinical relevance
- Current or recent history of drug or alcohol abuse
- Pregnant, planning to be pregnant, or lactating females or women of childbearing potential unwilling to commit to use of a medically approved form of contraception
Where it is running
- Illinois Institute of Technology - Institute for Food Safety and Health — Chicago, Illinois, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.